Back
Knowledge

The future of life science migrations: from one-off projects to continuous, AI-assisted pipelines

For decades, data migration in the life sciences has been synonymous with complex, manual, and resource-heavy projects. Whether moving from legacy systems to a new QMS or transferring data into a validated Veeva environment, the process has often required painstaking mapping, manual quality checks, and a lot of late nights.

But as the industry accelerates its shift to the cloud, we're witnessing a quiet transformation, one that is reshaping migrations from isolated events into standardized, continuous processes, increasingly supported by automation and artificial intelligence.

The cloud as a catalyst for standardization

The move to cloud platforms, especially validated systems like Veeva, has triggered a new need (and opportunity) for data standardization. Life science companies no longer want just to lift and shift data. Instead, they want clean, consistent, and structured information that supports global harmonization, automation, and compliance.

This trend is leading to a harmonization around common data models and metadata structures. Where migrations used to be bespoke and tool-specific, they’re now being built on shared foundations. This unlocks two major opportunities:

  1. Reusable migration frameworks, reducing cost and time.
  2. The emergence of continuous migration pipelines, where data flows are more similar to DevOps pipelines than one-time projects.

From projects to pipelines

As a result, we’re seeing the rise of what could be called Migration as a Process rather than Migration as a Project. Data doesn’t just move once. It’s continuously cleansed, transformed, validated, and transferred in smaller, more frequent batches, whether during system consolidation, cloud onboarding, or data quality improvements.

This shift has several benefits:

  • Reduced risk: Smaller, incremental moves reduce the chance of massive failures.
  • Better validation: Continuous pipelines allow more automated testing and validation at every stage.
  • Faster time to value: Teams can start working in new systems earlier, with clean, structured data already in place.

The role of AI in the new migration landscape

Artificial Intelligence is already playing a key role in this evolution. From auto-classifying documents and mapping metadata, to identifying duplicates or missing fields, AI is helping reduce the manual overhead and improving data quality.

For example:

  • AI models can read documents and auto-populate metadata fields.
  • AI & Machine learning can spot anomalies in migration outputs before they cause validation issues.
  • AI-powered bots can monitor audit logs to ensure data integrity during the migration process.

Rather than replacing migration experts, AI augments them, making the entire process smarter, faster, and more reliable.

M&A and the case for ad-hoc migrations

Of course, not all migrations can be standardized. Mergers and acquisitions, system decommissions, or divestitures still require tailored, ad-hoc migration strategies. In these cases, speed and flexibility matter more than standardization.

But even here, lessons from standardized migrations can apply. Pre-built components, AI tooling, and templated approaches can accelerate timelines and reduce risk, even when the migration is a one-time event.

What this means for life science companies

For life science organizations, the message is clear. If you treat data migrations as isolated events, you're missing an opportunity. The future lies in building the foundation for continuous, automated, and AI-enhanced migration pipelines, capable of handling not only cloud transformations but also ongoing data optimization and system evolution.

It's time to stop seeing migration as a hurdle and start treating it as an enabler of data-driven transformation.


Nick Larsen
Director, Technical Services
Contact
Linkedin

Explore other articles

Get in touch

We enjoy sharing our knowledge. Get in touch to find out how Epista can add value to your Life Science company.